drugset / Trial / NCT00045760

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

NCT00045760

Phase 4 Completed Eli Lilly and Company
Treatment

Summary

Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.

Timeline

Start
2002-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Drotrecogin alfa (activated) Protein / enzyme biologic 24 ug/kg Intravenous